MT 6345 / Tanabe Pharma - LARVOL DELTA

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects (clinicaltrials.gov) - P1; N=52; Terminated; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; N=120 ➔ 52; Recruiting ➔ Terminated; Preclinical finding

Clinical • Enrollment change • Trial termination